During a live event, Seth M. Pollack, MD, and participants discussed 2 investigational agents for recurrent diffuse tenosynovial giant cell tumor and how dosing format, treatment duration, and reimbursement could shape the choice among targeted therapies.

A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.

RYZ101, a targeted alpha radiopharmaceutical, boosts progression-free survival in SSTR+ GEP-NETs after progression, offering a promising post-¹⁷⁷Lu option.

Natera’s blood test analyzes cell-free DNA to screen for several cancer types from a single sample.

A Japanese study found favorable sensitivity and specificity for recurrence of melanoma based on presence of melanoma-specific markers in circulating tumor DNA.

Theodore Wagener, PhD, of The Ohio State University discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.

"AI will not replace oncologists; it will help interpret complex data and design more precise, adaptive, personalized cancer treatment," the authors write.

The phase 2 NRG-BR002 failed to improve outcomes with targeted radiotherapy to oligometastases; the phase 3 portion will not proceed.